Heartland Advisors recently published its Q1 2026 investor letter for the Heartland Opportunistic Value Equity Strategy, highlighting market shifts and individual stock performances. During the first quarter, the strategy realized a 3.66% appreciation, outperforming the Russell 3000 Value Index’s gain of 2.23%. While broader market volatility was triggered by geopolitical events in the Middle East, the fund maintained its focus on bottom-up fundamental analysis rather than speculating on macro trends like oil prices.
Managed Care Headwinds and Elevance Health’s Performance
A notable detractor during the quarter was Elevance Health, Inc. (NYSE:ELV). As of June 26, 2026, the company’s shares closed at $395.18, representing a market capitalization of $85.81 billion. Over the preceding month, ELV registered a -1.86% return, though it maintained a modest 52-week gain of 1.60%. The managed care insurer has faced industry-wide headwinds, including elevated healthcare utilization rates and persistent medical cost inflation.
Additionally, policy adjustments affecting enrollment mixes within Medicaid and the Affordable Care Act (ACA) exchanges have pressured operating margins across the entire health insurance sector. These factors have disproportionately impacted smaller competitors, while larger players like Elevance Health are positioned to leverage their scale to capture additional market share long-term.
Valuation Disconnect and Strategic Outlook
Despite short-term headwinds, Heartland Advisors views Elevance Health as a highly resilient player. The company’s management continues to execute share buybacks, signaling confidence in its capital structure and long-term earnings capacity. Currently, the stock trades at a 30% discount to the Russell 3000 Value Index based on forward 12-month earnings estimates. Historically, ELV has traded on par with this benchmark during mature economic cycles, pointing to a potential valuation mismatch.
In response to these conditions, the fund upgraded its position by shifting capital from smaller, more vulnerable peers into Elevance. This move was driven by ELV’s superior balance sheet strength and scale advantages. While the rise of AI-driven stocks has dominated recent market gains, value managers highlight managed care giants like Elevance as high-quality defensive plays with significant embedded earnings potential.
The Impact of Medicaid Redetermination and Utilization Trends
The broader managed care sector is currently grappling with the aftermath of Medicaid redeterminations, which began following the end of federal continuous enrollment provisions. This transition has shifted many former Medicaid recipients onto individual ACA plans or employer-sponsored coverage, causing fluctuations in medical loss ratios (MLRs) for insurers. For a diversified insurer like Elevance, navigating this shift requires precise pricing and risk assessment strategies. While utilization spikes in outpatient surgeries and orthopedic procedures have temporarily elevated costs, the long-term trend favors consolidated, scaled providers who can negotiate favorable reimbursement rates with hospital networks.
Conclusion: A Value Opportunity in a Defensive Sector
For long-term investors, the current discount on Elevance Health represents a classic value setup. When high-valuation momentum stocks dominate the market, defensive sectors like healthcare services often present attractive entry points. With strong capital allocation, ongoing buybacks, and a dominant position under the Blue Cross Blue Shield brand, Elevance is well-positioned to weather cyclical headwinds and emerge as a beneficiary of consolidation in the healthcare space.
